Diaper Cream, ZnO-Based

Overview

Diaper rash creams, ointments and pastes with zinc oxide as the active ingredient, usually at 10 to 40 percent. This is the zinc-oxide row of the Row 7 / Row 8 pair. The attribution of lead and cadmium to the zinc oxide platform is a Step 0 lock framing, not a finding of the sources on this page. The only measurements of finished products currently on file are four consumer-commissioned single-unit laboratory reports and a consumer-advocacy chart of eleven products, all grey literature. No peer-reviewed survey of metals in finished zinc oxide diaper creams is on file. The regulatory texts on file set no heavy-metal limit for the finished product when it is sold as an over-the-counter skin-protectant drug. Ingredient-level specifications exist for zinc oxide.

This page is a Step 0 lock scaffold for Cat 2 Row 8. Literature evidence will be populated as routed source pages accumulate per the synthesis workflow. The Step 0 lock document at Category2_Clean_vs_Contaminated_Splits.md is the canonical reference for the row’s clean-vs-contaminated framing and platform attribution.

Who this page is for

Brand legal teams evaluating HMT&C certification for the Diaper Cream, ZnO-Based row need to know what the cited literature reports per panel metal, what the applicable regulatory caps are, and how this row relates to its clean-contaminated pair (when applicable). Retailer compliance teams stocking the children’s personal care aisle need the row-level assortment-eligibility view. HMT&C certification thresholds for products in this row are developed under the certification program at heavymetalcertified.com, not on this page.

Evidence summary

Evidence summary

The table below summarizes what the peer-reviewed and government literature cited on this page reports for heavy-metal concentrations in Diaper Cream, ZnO-Based. Values are pulled directly from cited sources without re-aggregation. This page publishes literature evidence only, not certification thresholds.

Methodology rules for speciation, basis preservation, non-detect handling, and source pooling are stated in the Methodology section above and apply to every row below.

Source Evidence Inventory

Finished-product measurements on file are grey literature (evidence tier C). Each is one retail unit analysed by ICP-MS and reported as received (finished product as sold). Arsenic and mercury are totals, not speciated. The ’<’ values are laboratory reporting values.

The same author’s comparison chart (Consumer-advocacy comparison chart of lead, cadmium, mercury and arsenic in eleven diaper creams (updated January 2026)) lists eleven products with rounded lead from 136 to 4,657 ppb and cadmium from 14.1 to 510 ppb. Mercury was below 5 ppb throughout, and arsenic was below 10 ppb except for one product at 52 ppb. Four chart values match the reports above. The other seven have no laboratory report on file, and for five of them the chart page does not state the zinc oxide content. The chart includes no product without zinc oxide. These four reports and one chart cannot support a category distribution, a detection rate or a comparison with the non-zinc-oxide row.

Dermal-pathway evidence on file concerns zinc, the major element of the active ingredient, not lead or cadmium. On intact adult skin, zinc from zinc oxide reaches the viable epidermis in small amounts (Influence of two vehicles for zinc oxide on zinc absorption through intact skin and wounds, Human Epidermal Zinc Concentrations after Topical Application of ZnO Nanoparticles in Sunscreens, Opinion on Zinc oxide (nano form), COLIPA S 76). Systemic uptake is much greater through full-thickness rat wounds (Influence of two vehicles for zinc oxide on zinc absorption through intact skin and wounds). A preterm infant developed serum zinc of 427 µg/dL during zinc oxide ointment use on eroded diaper dermatitis while also taking oral zinc (Early Intervention by a Ward Pharmacist for the Hyperzincemia Caused by Zinc Oxide Ointment in a Infant with Diaper Dermatitis: A Case Report). UVB injury increased zinc uptake in mouse skin (UVB exposure enhanced the dermal penetration of zinc oxide nanoparticles and induced inflammatory responses through oxidative stress mediated by MAPKs and NF-κB signaling in SKH-1 hairless mouse skin), while SCCS reports no damaged-versus-intact difference in the pig and human models it reviewed. No source on file measures lead or cadmium absorption from a diaper cream.

Regulatory instruments cited by the sources on this page, with the basis each applies to:

Which instrument applies depends on how the product is marketed. In the United States, zinc oxide diaper-rash products are over-the-counter drugs under the skin-protectant monograph. In Canada, licensed zinc oxide diaper-rash products are natural health products under the monograph and Quality Guide. A product marketed as a cosmetic falls under the cosmetic guidance in each jurisdiction.

Supporting evidence and scope

Pending: regenerated by tools/evidence/apply-product-broad-context.mjs once broad-scope Cat 2 sources route to this page.

Federal/Regulatory Limits vs Field Findings

Pending. Cat 2 regulatory landscape is fragmented: cosmetics under FDA FD&C Act adulteration provisions (no binding finished-product heavy-metal limits); sunscreens under FDA OTC drug monograph; toothpaste under FDA cosmetic + OTC drug regulation; state-level cosmetic heavy-metal laws (Washington TFCA 2025, New York TCCP). EU 1223/2009 Annex II/III addresses cosmetic ingredient restrictions but not finished-product action levels. Awaiting agency-page ingest.

Controls and mitigation

The Cat 2 Step 0 lock framework distinguishes clean-formulation rows from contaminated-platform rows. For this row, the levers below are ordered by impact magnitude based on the literature evidence base and per the Step 0 lock attribution of platform-level metal load. Brand-legal teams evaluating HMT&C certification eligibility for this row should treat the formulation/sourcing levers as the dominant compliance pathway.

1. Sourcing levers (highest impact): platform-ingredient supplier selection. Pre-screened low-impurity grades of Pb/Cd -carrying ingredients are commercially available at premium price; the gap between cosmetic-grade and pharmaceutical-grade specifications is material.
2. Refining levers for the platform ingredient class.
3. Formulation levers: reduce the platform-ingredient fraction of the finished product where the function permits.
4. Testing/QC levers: lot-level ICP-MS testing on raw materials and finished product. Cosmetic-grade supply chains routinely COA at the µg/kg level when specified.
5. Regulatory levers (not brand-controllable): supporting state-level Pb/Cd/Hg-in-cosmetics standards drives industry-wide tightening.

Pair relationship + platform attribution

This is the contaminated row of a Cat 2 clean-contaminated pair. The clean counterpart is Row 7 (Diaper Cream, Non-ZnO). The categorical metal-load difference is attributable to platform ingredient(s) carrying load on Pb, Cd. Certification threshold decisions for this row and its clean counterpart are made separately under the certification program and are not published on this public page.

How standards math uses this page

This page reports what the peer-reviewed and government literature says about heavy-metal concentrations in this product category; it publishes no certification thresholds of its own. Certification criteria are set separately under the Heavy Metal Tested & Certified program at heavymetalcertified.com, which reads this page as its literature baseline. The two are kept apart by design, so this page remains an independent record of the evidence rather than a justification for any threshold.

Historical recalls and enforcement

Cat 2 (children’s personal care) regulatory enforcement is fragmented: cosmetics fall under FDA FD&C Act adulteration provisions without binding finished-product heavy-metal action levels; sunscreens fall under FDA OTC drug monograph; toothpaste falls under FDA cosmetic + OTC drug regulation. State-level enforcement is more active: Washington State Toxic-Free Cosmetics Act 2025 sets heavy-metal limits for cosmetic products sold in Washington; New York Toxic Children’s Cosmetic Products Act sets limits for children’s makeup. California Prop 65 enforcement actions on cosmetics (lip balm, lipstick, eye products) have established practical compliance thresholds via settlement agreements. EU Cosmetic Regulation 1223/2009 Annex II/III addresses cosmetic-ingredient restrictions but not finished-product action levels. Individual brand recall actions are not enumerated here; the recalls are framed as regulatory events that establish the operative compliance landscape.

Methodology

This page reports what the cited sources say about heavy-metal concentrations in the Diaper Cream, ZnO-Based row. Speciation is non-substitutable (iAs vs tAs, MeHg vs tHg, Cr-VI vs total Cr). Basis is preserved (finished-product as sold). Non-detect handling follows each source’s convention. Pooling avoided across LOD/LOQ, period, geography, and analytical-basis differences. HMT&C certification thresholds for products in this row are developed under the certification program at heavymetalcertified.com, not on this page; this public page reports literature evidence only.

The non-ingestion exposure pathways relevant to this row (dermal, inhalation, accidental-ingestion, and trans-placental) are documented at Cat 2 (Children Personal Care) non-ingestion exposure pathways.

References

Works cited in this page’s text, in first-appearance order. See Sources for this page’s source inventory. Each title links to a source record with bibliographic details, reported findings, and document provenance.

1. Consumer-advocacy comparison chart of lead, cadmium, mercury and arsenic in eleven diaper creams (updated January 2026)Rubin T · Lead Safe Mama, LLC (tamararubin.com), posted 21 September 2025, updated 18 January 2026; chart image dated 17 January 2026 · 2026 · tamararubin.comConsumer advocacy testing
2. Influence of two vehicles for zinc oxide on zinc absorption through intact skin and woundsÅgren MS · Acta Dermato-Venereologica 71(2):153-156 · 1991 · doi.org/10.2340/0001555571153156Peer-reviewed
3. Human Epidermal Zinc Concentrations after Topical Application of ZnO Nanoparticles in SunscreensKhabir Z, Holmes AM, Lai YJ, Liang L, Deva A, Polikarpov MA, et al. · International Journal of Molecular Sciences 22(22):12372 · 2021 · doi.org/10.3390/ijms222212372Peer-reviewed
4. Opinion on Zinc oxide (nano form), COLIPA S 76Scientific Committee on Consumer Safety · SCCS/1489/12, adopted 18 September 2012, revision of 11 December 2012, European Commission · 2012 · health.ec.europa.euGovernment
5. Early Intervention by a Ward Pharmacist for the Hyperzincemia Caused by Zinc Oxide Ointment in a Infant with Diaper Dermatitis: A Case ReportYasugi M, Ooi H, Asai Y, Konishi T, Otobe Y, Kitamura S, et al. · Yakugaku Zasshi 146(1):85-89 · 2026 · doi.org/10.1248/yakushi.25-00096Peer-reviewed
6. UVB exposure enhanced the dermal penetration of zinc oxide nanoparticles and induced inflammatory responses through oxidative stress mediated by MAPKs and NF-κB signaling in SKH-1 hairless mouse skinPal A, Alam S, Chauhan LKS, Saxena PN, Kumar M, Ansari GN, et al. · Toxicology Research 5(4):1066-1077 · 2016 · doi.org/10.1039/c6tx00026fPeer-reviewed

Sources

Source records associated with this topic. Inclusion does not establish that every finding applies to this product or ingredient. References above identify works cited in the text.

Update history

No substantive edit history is available in this build. The full commit record is available in git.